VBIT-12 is primarily used in research settings for its ability to inhibit necroptosis, a form of programmed cell death. This makes it a valuable tool in studying diseases where cell death plays a critical role, such as neurodegenerative disorders, ischemic injuries, and inflammatory conditions. It has shown potential in protecting cells in models of retinal degeneration, suggesting possible applications in treating eye diseases like glaucoma. Additionally, VBIT-12 is used to investigate the role of RIPK1 and RIPK3 kinases in cellular signaling pathways, helping to clarify their involvement in inflammation and tissue damage. Due to its stability and effectiveness in cellular and animal models, it supports the development of targeted therapies aimed at controlling pathological cell death.